Shukra Pharmaceuticals board approves preferential issue of warrants to promoters

On October 3, 2025, Shukra Pharmaceuticals Limited's board of directors approved a preferential issue of 4,643,000 convertible equity warrants. These warrants, each carrying the right to subscribe to one equity share, will be issued to promoter shareholders. The total value of this issue is approximately INR 15,78,62,000, with each warrant priced at INR 34. This issuance is contingent upon receiving shareholder approval and adherence to applicable laws, including SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

The warrants will be allotted on a private placement basis, with an initial payment of 25% of the issue price due at subscription. The remaining 75% will be payable upon the exercise of the warrants. The tenure for exercising these warrants will not exceed 18 months from the date of allotment. If not exercised within this period, the warrants will lapse, and the initial payment will be forfeited.

The board also set Wednesday, October 1, 2025, as the relevant date for the preferential issue, considering October 2, 2025, was a public holiday. An Extra Ordinary General Meeting (EOGM) to consider these proposals will be held on Saturday, November 1, 2025, via video conferencing, with Rupal Patel appointed as the scrutinizer.